TY - JOUR
T1 - Temporal changes in coronary plaque as assessed by an artificial intelligence–based optical coherence tomography
T2 - from the first-in-human trial on DREAMS 3G scaffold
AU - Garcia-Garcia, Hector M.
AU - Waksman, Ron
AU - Melaku, Gebremedhin D.
AU - Garg, Mohil
AU - Beyene, Solomon
AU - Wlodarczak, Adrian
AU - Kerai, Ajay
AU - Levine, Molly B.
AU - van der Schaaf, René J.
AU - Torzewski, Jan
AU - Ferdinande, Bert
AU - Escaned, Javier
AU - Iglesias, Juan F.
AU - Bennett, Johan
AU - Toth, Gabor G.
AU - Joner, Michael
AU - Toelg, Ralph
AU - Wiemer, Marcus
AU - Olivecrona, Göran
AU - Vermeersch, Paul
AU - Haude, Michael
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Aims The aim of the study is to assess the impact of the baseline plaque composition on the DREAMS 3G luminal late loss and to compare the serial plaque changes between baseline and 6 and 12 months (M) follow-up. Methods A total of 116 patients were enrolled in the BIOMAG-I trial. Patients were imaged with optical coherence tomography and results (OCT) pre- and post-DREAMS 3G implantation and at 6 and 12 M. OCTPlus software uses artificial intelligence to assess composition (i.e. lipid, calcium, and fibrous tissue) of the plaque. The differences between the OCT-derived minimum lumen area (MLA) post-percutaneous coronary intervention and 12 M were grouped into three terciles. Patients with larger MLA differences at 12 M (P = 0.0003) had significantly larger content of fibrous tissue at baseline. There was a reduction of 24.8% and 20.9% in lipid area, both P < 0.001, between the pre-DREAMS 3G OCT and the 6 and 12 M follow-up. Conversely, the fibrous tissue increased by 48.4% and 36.0% at 6 and 12 M follow-up, both P < 0.001. Conclusion The larger the fibrous tissue in the lesion at baseline, the larger the luminal loss seen at 6 and 12 M. Following the implantation of DREAMS 3G, favourable healing of the vessel coronary wall occurs as shown by a decrease in the lipid area and an increase in fibrous tissue.
AB - Aims The aim of the study is to assess the impact of the baseline plaque composition on the DREAMS 3G luminal late loss and to compare the serial plaque changes between baseline and 6 and 12 months (M) follow-up. Methods A total of 116 patients were enrolled in the BIOMAG-I trial. Patients were imaged with optical coherence tomography and results (OCT) pre- and post-DREAMS 3G implantation and at 6 and 12 M. OCTPlus software uses artificial intelligence to assess composition (i.e. lipid, calcium, and fibrous tissue) of the plaque. The differences between the OCT-derived minimum lumen area (MLA) post-percutaneous coronary intervention and 12 M were grouped into three terciles. Patients with larger MLA differences at 12 M (P = 0.0003) had significantly larger content of fibrous tissue at baseline. There was a reduction of 24.8% and 20.9% in lipid area, both P < 0.001, between the pre-DREAMS 3G OCT and the 6 and 12 M follow-up. Conversely, the fibrous tissue increased by 48.4% and 36.0% at 6 and 12 M follow-up, both P < 0.001. Conclusion The larger the fibrous tissue in the lesion at baseline, the larger the luminal loss seen at 6 and 12 M. Following the implantation of DREAMS 3G, favourable healing of the vessel coronary wall occurs as shown by a decrease in the lipid area and an increase in fibrous tissue.
KW - bioresorbable stent
KW - de novo coronary lesion
KW - drug-eluting stent
KW - minimum lumen area
KW - optical coherence tomography
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85189376835&partnerID=8YFLogxK
U2 - 10.1093/ehjci/jead299
DO - 10.1093/ehjci/jead299
M3 - Article
C2 - 37936296
AN - SCOPUS:85189376835
SN - 2047-2404
VL - 25
SP - 491
EP - 497
JO - European Heart Journal Cardiovascular Imaging
JF - European Heart Journal Cardiovascular Imaging
IS - 4
ER -